Ward WH, Farma JM. Cutaneous Melanoma: Etiology and Therapy. Brisbane (AU): Codon Publications; 2017. https://www.ncbi.nlm.nih.gov/books/NBK481860/https://doi.org/10.15586/codon.cutaneousmelanoma.2017. Accessed 30 April 2020.
Avilés-Izquierdo JA, Molina-López I, Rodríguez-Lomba E, Marquez-Rodas I, Suarez-Fernandez R, Lazaro-Ochaita P. Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma. J Am Acad Dermatol. 2016;75(5):967–74. https://doi.org/10.1016/j.jaad.2016.07.009.
Article
PubMed
Google Scholar
National Cancer Institute. Surveillance, Epidemiology, and End Results Program website. Cancer stat facts: melanoma of the skin. 2020. https://seer.cancer.gov/statfacts/html/melan.html. Accessed 29 April 2020.
Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:3–9. https://doi.org/10.1016/j.clindermatol.2008.09.001.
Article
PubMed
Google Scholar
Chiaravalloti AJ, Jinna S, Kerr PE, Whalen J, Grant-Kels JM. A deep look into thin melanomas: what’s new for the clinician and the impact on the patient. Int J Womens Dermatol. 2018;4(3):119–21. https://doi.org/10.1016/j.ijwd.2018.01.003.
CAS
Article
PubMed
PubMed Central
Google Scholar
Coit DG, Thompson JA, Albertini MR, et al. Cutaneous Melanoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. 2019. https://www.nccn.org/professionals/physician_gls/default.aspx#melanoma. Accessed 6 January 2020.
Klapperich ME, Bowen GM, Grossman D. Current controversies in early-stage melanoma: questions on management and surveillance. J Am Acad Dermatol. 2019;80(1):15–25. https://doi.org/10.1016/j.jaad.2018.03.054.
Article
PubMed
Google Scholar
Gardner LJ, Strunck JL, Wu YP, Grossman D. Current controversies in early-stage melanoma: questions on incidence, screening, and histologic regression. J Am Acad Dermatol. 2019;80(1):1–12. https://doi.org/10.1016/j.jaad.2018.03.053.
Article
PubMed
Google Scholar
Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208–50. https://doi.org/10.1016/j.jaad.2018.08.055.
Article
PubMed
Google Scholar
Barbour AA, Guminski A, Liu W, Menzies S, Morton R. Cancer Council Australia Melanoma Guidelines Working Party. What is the ideal setting, duration and frequency of follow-up for melanoma patients? https://wiki.cancer.org.au/australia/Guidelines:Melanoma. Accessed 26 Aug 2020.
Leiter U, Buettner PG, Eigentler TK, et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol. 2012;66(1):37–45. https://doi.org/10.1016/j.jaad.2010.09.772.
Article
PubMed
Google Scholar
Matsumoto M, Secrest A, Anderson A, et al. Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol. 2018;78(4):701–9. https://doi.org/10.1016/j.jaad.2017.11.033.
Article
PubMed
Google Scholar
Waldmann A, Nolte S, Geller AC, et al. Frequency of excisions and yields of malignant skin tumors in a population-based screening intervention of 360,288 whole-body examinations. Arch Dermatol. 2012;148:903–10. https://doi.org/10.1001/archdermatol.2012.893.
Article
PubMed
Google Scholar
Chao L, Patterson S, Rademaker A, Liu D, Kundu R. Melanoma perception in people of color: a targeted educational intervention. Am J Clin Dermatol. 2017;18(3):419–27. https://doi.org/10.1007/s40257-016-0244-y.
Article
PubMed
Google Scholar
McGuire ST, Secrest AM, Andrulonis R, Ferris LK. Surveillance of patients for early detection of melanoma: patterns in dermatologist vs patient discovery. Arch Dermatol. 2011;147(6):673–8. https://doi.org/10.1001/archdermatol.2011.135.
Article
PubMed
Google Scholar
Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6(8):608–21. https://doi.org/10.1016/S1470-2045(05)70283-7.
Article
PubMed
Google Scholar
Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14(6):1924–33. https://doi.org/10.1245/s10434-007-9347-2.
Article
PubMed
Google Scholar
Deckers EA, Hoekstra-Weebers JEHM, Damude S, et al. The MELFO study: a multicenter, prospective, randomized clinical trial on the effects of a reduced stage-adjusted follow-up schedule on cutaneous melanoma IB-IIC patients-results After 3 Years. Ann Surg Oncol. 2020;27(5):1407–17. https://doi.org/10.1245/s10434-019-07825-7.
Article
PubMed
Google Scholar
Murchie P, Nicolson MC, Hannaford PC, Raja EA, Lee AJ, Campbell NC. Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial. Br J Cancer. 2010;102(10):1447–555. https://doi.org/10.1038/sj.bjc.6605638.
CAS
Article
PubMed
PubMed Central
Google Scholar
Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Brit J Dermatol. 2010;163(2):238–56. https://doi.org/10.1111/j.1365-2133.2010.09883.x.
CAS
Article
Google Scholar
Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Wellington, New Zealand: New Zealand Guidelines Group; 2008. https://www.health.govt.nz/system/files/documents/publications/melanoma-guideline-nov08-v2.pdf. Accessed 1 February 2020.